Ro to offer lower-price vials of weight loss drug Zepbound

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk ...
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail ...